Robert W. Carlson, MD, has disclosed that he is the Chief Executive Officer of NCCN, but otherwise has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Eric Jonasch, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb Company, Exelixis Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Laboratories, Inc.; honoraria from Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Laboratories, Inc.; and grant/research support from Exelixis Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Pfizer Inc.
Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–1068.
Motzer RJ, Hutson TE, McCann L. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:1769–1770.
Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.